1. Introduction {#s0005}
===============

One quarter of all cases of pediatric malignancies is acute lymphoblastic leukemia (ALL) ([@bb0075]). Corticosteroids and methotrexate (MTX) are used in the treatment of ALL and affect bone metabolism. MTX causes increase resorption and inhibition of bone formation. Corticosteroids cause a decrease in osteoblastic activity and have direct effect on bone matrix. In addition, children undergoing cancer therapy may have limited physical activity and suffer from malnutrition during their illness, further influencing the achievement of potential peak bone mass ([@bb0040]).

The treatment of ALL is one of the most complex treatment plans used in any type of cancer. It is divided into three phases, starting with the *induction phase*, followed by the *consolidation phase* (or intensification) and finally *continuation phase* according to total therapy study XV for newly diagnosed patients with acute lymphoblastic leukemia:--Induction phase (6--7 weeks) consists of a combination of several medications, most often a steroid (*dexamethasone* or *prednisone*).--Consolidation phase (8 weeks) uses most often a steroid (*dexamethasone* or *prednisone*), *vincristine*, an *anthracycline* (*daunorubicin*, *epirubicin* or *idarubicin*) and *asparaginase*. Other medications may be used, such as *cytarabine*, *cytoxan*, *methotrexate* and *rituximab* but is more variable in its schedule and depends on the particular subtype of ALL.--Continuation phase (120 weeks/female--146 weeks/male) consists of *6-MP*, *methotrexate*, *vincristine*, and *prednisone*, given over a period of 2 to 3 years. Studies found no benefit to increasing this time, outcomes become worse if the maintenance period was shorter. Continuation therapy is not given for Burkitt\'s lymphoma leukemia, as this subtype has a high cure rate with induction and consolidation therapy alone ([@bb0025]).

Osteoporosis is considered a multifactorial disease resulting from interactions between genetic and environmental factors. It is characterized by the increased risk of fragility fractures and reduced bone mineral density (BMD). The genetic factors play key functions (50--85%) in the pathogenesis of osteoporosis. Vitamin-D receptor (VDR) gene has been considered as an important candidate gene in the modification of BMD and the development of osteoporosis ([@bb0080]). The VDR gene is located on chromosome 12q13 (100 kb) ([@bb0065]). Variation in DNA sequence of the coding and non-coding region by a single nucleotide polymorphism (SNP) may influence the stability, quantity and activity of the VDR protein and rate of VDR mRNA formation. Over 470 SNPs have been reported in the human VDR gene ([@bb0070]).

The 3′ un-translated region of the VDR gene includes TaqI, BsmI and ApaI gene polymorphisms ([@bb0055]). Taq1 is located in exon 9 ([@bb0060]), BsmI is located between exon VIII and the three non-coding regions. There is a strong linkage disequilibrium between the BsmI and TaqI polymorphism such that the B allele (mutant) is usually associated with the t allele (mutant) and the BB genotype is almost equivalent to the tt genotype ([@bb0005]). The ApaI is located in intron 8 at the 3′-end of the VDR gene. BsmI and ApaI are considered as silent single nucleotide polymorphisms (SNPs). These polymorphisms don\'t change the amino acid sequence of the encoded protein, however, they may affect gene expression through regulation of mRNA stability ([@bb0035]). Cdx-2 and GATA are common variants in the promoter region around exons 1e and 1a and are often analyzed as a haplotype block. Both of them are located at the 5′-end of the VDR gene ([@bb0020]). The aim of the present work was to detect the frequency of the VDR polymorphism and their association with BMD in Egyptian pediatric acute lymphoblastic leukemia patients.

2. Patients and methods {#s0010}
=======================

2.1. Patient selection {#s0015}
----------------------

The study group consisted of forty patients with newly diagnosed ALL. They included 28 (70%) males and 12 (30%) females, their age ranged from 4 to 18 years. All cases were recruited from the clinical pathology and radiology departments of the children\'s cancer hospital, Cairo, Egypt. Patients\' guardians were approached and accepted their participation in the study and gave their written consent. All patients were treated according to total XV protocol and received calcium & vitamin D supplements. According to the presence of initial BMD, twenty-six of these cases were further analyzed with regards to the effect of various genotypes and haplotypes on BMD.

2.2. Measurement of bone mineral density (BMD) {#s0020}
----------------------------------------------

Dual energy X-ray absorptiometry (DXA) provided estimates of BMD of the lumbar spine. All DXA results were expressed as age matched and sex-matched SDS, Special pediatric software was used for children who weighed less than 30 kg.

2.3. VDR gene polymorphism {#s0025}
--------------------------

Genomic DNA was extracted by using salting out technique ([@bb0045]). Three SNPs at the 3′-end of the VDR gene (BsmI rs1544410, ApaI rs739837and TaqI rs731236) and two SNPs at the 5′-end (Cdx-2 rs11568820 and GATA rs4516035) were analyzed using Allelic Discrimination Assay.

Real Time PCR was performed using 12.5 μl TaqMan® Universal PCR Master Mix, No AmpErase UNG (2 ×), 1.25 μl SNP Genotyping Assay mix (TaqMan probes) (20 ×), 10.25 μl Dnase Free Water and 1 μl DNA (20 ng), to bring the final reaction volume to 25 μl. According to the manufacturer\'s instructions and the information in the Applied Biosystems manual, the thermal conditions were as follows (initial denaturation at 95 °C for 10 min, 40 cycles of 92 °C for 15 s (denaturation) and 60 °C for I min (annealing/extension) using 7500 Applied Biosystems fast Real-Time PCR system.

2.4. Statistical analysis {#s0030}
-------------------------

Descriptive statistics for both measurements in each gene was done using mean and standard deviation. A repeated measures ANOVA model was done to check if there was statistical significant difference between the genotype-time interactions. The difference between means of both groups in each genotype was done using paired t-test. P-values cut off for significance was set at 0.05 for all tests. All statistical procedures have been done using SPSS v 20.

3. Results {#s0035}
==========

The genotype frequencies of the 3′ and 5′ VDR SNPs are shown in [Table 1](#t0005){ref-type="table"}. We observed 8 possible haplotypes at the 3′-end and 4 possible haplotypes at the 5′-end. The haplotype frequencies for the three SNPs at the 3′-end and the 5′-end of the VDR gene are shown in [Table 2](#t0010){ref-type="table"}. According to presence of initial BMD before treatment twenty-six cases 17 (65%) males, 9 (35%) females were analyzed further for the effect of various genotypes and haplotypes on the BMD after vitamin D administration.

The TaqI genotype distribution in this group of patients were TT (23%), Tt (54%) and tt (23%) ([Table 3](#t0015){ref-type="table"}). The Tt genotype was found to be significantly associated with increased BMD as compared to the other two genotypes (P = 0.0420) ([Fig. 1](#f0005){ref-type="fig"} & [Table 3](#t0015){ref-type="table"}). The correction between Z score of BMD before and during treatment for BsmI, ApaI, Cdx-2 and GATA, various genotypes did not reveal any statistical significance ([Table 3](#t0015){ref-type="table"}). No significant association was found between BMD before and during treatment and haplotype distribution for the three SNPs at the 3′-end of the VDR gene ([Table 4](#t0020){ref-type="table"}) and for the two SNPs at the 5′-end ([Table 5](#t0025){ref-type="table"}).

4. Discussion {#s0040}
=============

We analyzed VDR gene polymorphisms in 40 Egyptian pediatric ALL cases.

The TaqI genotype frequencies were TT 23%, Tt 54% and tt 23%. [@bb0010] reported that in 143 healthy Indian individuals, the TaqI genotype frequencies were TT 49%, Tt 43%, tt 8%. In a Japanese Population based Osteoporosis Study (JPOS), 1434 women were analyzed. TaqI genotype frequencies were 78.7%, 19.6% and 1.7 for TT, Tt and tt respectively ([@bb0050]). In 78 unrelated normal Syrian individuals, the TaqI genotype distribution was 36%, 58% and 6%for TT, Tt and tt, respectively ([@bb0030]). The prevalence of the three BsmI genotypes in our patients was BB 19.2%, Bb 65.4% and bb 15.4%. In a study including 198 Korean girls diagnosed with adolescent Idiopathic scoliosis, the distribution frequency of BsmI was BB 25.3%, Bb 51.5%, bb 23.2% ([@bb0085]). P. Marozik et al. (2013) reported BB 22.2%, Bb 57.4% and bb 20.4% in the Belarusian women. In the present study, the prevalence of the three ApaI genotypes were AA 12%, Aa 27% and aa 61%. In a Japanese Population based Osteoporosis Study (JPOS), 1434 women were analyzed, ApaI genotype frequencies were AA 8.9%, Aa 41.0% and aa 50.1% ([@bb0050]). In 78 unrelated normal Syrian healthy population, the ApaI genotype distribution was 42%, 47% and 10% for AA, Aa and aa respectively ([@bb0030]). In the Belarusian women with osteoporosis, P. Marozik et al., 2013 found that the genetic frequencies of ApaI polymorphism were 42.6%, 44.4% and 13% for AA, Aa and aa respectively. This marked variability in the genotype frequencies can be explained in part by the ethnic differences and also by the various numbers of the cases analyzed in each report. In our work, the patients with Tt genotype had a significantly higher BMD in response to vitamin D supplements than patients with TT, tt genotypes. On the other hand no statistical significance was found between BsmI and ApaI genotypes and BMD. However the Bb genotype showed a trend towards an increase in BMD that didn\'t reach a statistical significance. Analyzing a large number of cases would clarify such correlation. To the best of our knowledge this is the first report on the correlation between the VDR 3′-end genotypes with BMD in Egyptian pediatric ALL. In the present work, the prevalence of the three Cdx-2 genotypes in our patients was GG 34.5%, GA 54% and AA 11.5%. In a study including 198 Korean girls diagnosed with adolescent Idiopathic scoliosis the frequency distribution of Cdx-2 were GG 68.6%, GA 24.7%, and AA 6.5% ([@bb0085]). The prevalence of the three GATA genotypes in our patients was AA 8%, AG 50% and GG 42%. To the best of our knowledge, no other reports were found analyzing the GATA genotypes. In our study, no statistical significance was detected between the various genotypes of Cdx-2 and GATA polymorphisms and BMD in Egyptian pediatric ALL patients.

In our patients eight possible haplotypes at VDR 3′-end were found. There was no association between any of these haplotypes and BMD. In a study by Te [@bb0090] he investigated the effect of treatment of acute lymphoblastic leukemia on BMD in sixty-nine Dutch children and reported 4 haplotypes at the 3′-end (baT, BAt, bAT and BAT). [@bb0015] studied a large population-based cohort of older Dutch individuals (923 men & women) and reported 3 haplotypes at VDR 3′-end (baT, BAt, bAT). Our patients showed 4 extra haplotypes than those reported by Te [@bb0090] (bAt, bat, BaT, Bat) and 5 more haplotypes compared to the study of [@bb0015] denoting the marked genetic variability of the Egyptians compared to Dutch population. In agreement with our results Te Winkel et al. and [@bb0015] didn\'t find any association between VDR3′-end haplotypes and BMD. In our patients, we detected 4 possible haplotypes at 5′-end. Te [@bb0090] reported 3 haplotypes (GA), (GG) and (AG). [@bb0015] reported 3 haplotypes GG, GA, AA. In our work, no statistical significant association was found between any of these haplotypes and BMD. On the contrary, Te [@bb0090] reported a lower BMD associated with haplotype (AG) and [@bb0015] reported an association between (GG) haplotype and increased mortality risk, which was partly explained by the occurrence of osteoporotic fracture. This discrepancy could be partially explained by the variability in the number of cases tested.

In conclusion, we investigated the association between VDR gene polymorphism and BMD in Egyptian patients with acute lymphoblastic leukemia. To the best of our knowledge this is the first report studying such association. Our study revealed a positive correlation between the heterozygous genotype of the TaqI gene and BMD and a trend towards increase BMD with Bb genotype. No statistical significance was found between the other VDR genotypes or haplotypes studied and BMD. Further studies on large number of cases are recommended to confirm these finding. In our patients more haplotypes were detected at the 3′-end of the VDR gene compared to those reported in other populations denoting the marked genetic heterogeneity in the Egyptian pediatric ALL patients.
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###### 

Vitamin D receptor (VDR) genotype frequencies in 40 Egyptian pediatric ALL cases.

Table 1

  VDR genotype frequencies (%) n = 40[a](#tf0005){ref-type="table-fn"}                                 
  ---------------------------------------------------------------------- -------------- -------------- --------------
  BsmI                                                                   BB             Bb             Bb
                                                                         (5/40)12.5%    (23/40)57.5%   (12/40)30%
  ApaI                                                                   AA             Aa             Aa
                                                                         (7/40)17.5%    (11/40)27.5%   (22/40)55%
  TaqI                                                                   TT             Tt             Tt
                                                                         (16/40)40%     (17/40)42.5%   (7/40)17.5%
  Cdx-2                                                                  GG             GA             AA
                                                                         (17/40)42.5%   (19/40)47.5%   (4/40)10%
  GATA                                                                   AA             AG             GG
                                                                         (5/40)12.5%    (16/40)40%     (19/40)47.5%

(BsmI; b = wild, B = mutant) (ApaI; A = wild, a = mutant) (TaqI; T = wild, t = mutant) (Cdx-; G = wild, A = mutant) (GATA; A = wild, G = mutant).

###### 

Vitamin D receptor (VDR) haplotype frequencies at the 3′-end and 5′-end in 40 Egyptian pediatric ALL cases.

Table 2

  VDR haplotype frequencies             
  --------------------------- ---- ---- ----
  baT                         26   GA   23
  BAt                         7         
  bAT                         19   GG   31
  BAT                         9         
  bAt                         7    AG   23
  bat                         19        
  BaT                         20   AA   12
  Bat                         23        

###### 

The frequencies and the correction between Z score of BMD before and during treatment for various genotypes of VDR SNPs.

Table 3

  Genotype frequencies (%)   BMD before treatment   BMD during treatment   P value                                   
  -------------------------- ---------------------- ---------------------- ----------------------------------------- --------
  BsmI                       bb 19.2%               − 0.780 ± .8167        − 0.860 ± 1.0991                          0.9150
  Bb 65.4%                   − 1.082 ± 1.4732       − 0.859 ± 1.2278       0.2970                                    
  Bb 15.4%                   − 1.100 ± 0.6164       − 1.175 ± 0.8221       0.8110                                    
  ApaI                       AA 12%                 − 0.800 ± 0.9539       − 0.567 ± 0.8737                          0.2220
  Aa 27%                     − 0.900 ± 1.5524       − 0.743 ± 1.1326       0.7630                                    
  Aa 61%                     − 1.125 ± 1.2168       − 1.044 ± 1.1905       0.7260                                    
  TaqI                       TT 23%                 − 0.667 ± 0.9136       − 1.233 ± 0.9812                          0.2060
  Tt 54%                     − 1.107 ± 1.4809       − 0.557 ± 1.1850       0.0420[⁎](#tf0010){ref-type="table-fn"}   
  tt 23%                     − 1.200 ± 1.0178       − 1.400 ± 0.9423       0.4230                                    
  Cdx-2                      GG 34.5%               − 1.100 ± 0.8000       − 1.056 ± 1.0026                          0.8560
  GA 54%                     − 1.186 ± 1.4930       − 1.007 ± 1.1552       0.4710                                    
  AA 11.5%                   − 0.067 ± 0.9074       0.000 ± 1.2490         0.9600                                    
  GATA                       AA 8%                  − 1.150 ± 0.2121       − 0.250 ± 0.7778                          0.2660
  AG 50%                     − 1.092 ± 1.5207       − 1.008 ± 1.1146       0.7630                                    
  GG 42%                     − 0.927 ± 1.0451       − 0.909 ± 1.2169       0.9520                                    

The difference was significant, P \< 0.05.

###### 

The correction between Z score of BMD before and during treatment with haplotype distributions for three SNPs at the 3′-end of the VDR gene (BsmI, ApaI and TaqI).

Table 4

  Haplotype (BsmI, ApaI, and TaqI)   Number   BMD before treatment   BMD during treatment   P value
  ---------------------------------- -------- ---------------------- ---------------------- ---------
  bat                                16       − 1.1438 ± 1.47376     − 0.7188 ± 1.23786     0.088
  baT                                17       − 1.0059 ± 1.40467     − 0.7941 ± 1.20751     0.452
  bAt                                6        − 1.1500 ± 1.53851     − 0.6333 ± 1.19944     0.261
  bAT                                10       − 0.8700 ± 1.34582     − 0.6900 ± 1.01593     0.612
  Bat                                19       − 1.1368 ± 1.36878     − 0.9053 ± 1.11129     0.223
  BaT                                14       − 1.1357 ± 1.48459     − 0.8071 ± 1.20030     0.188
  BAt                                6        − 1.1500 ± 1.53851     − 0.6333 ± 1.19944     0.261
  BAT                                7        − 0.9429 ± 1.50760     − 0.4857 ± 1.16251     0.239

###### 

The correction between Z score of BMD before and during treatment with haplotype distributions for two SNPs at the 5′-end of the VDR gene (Cdx-2 and GATA).

Table 5

  Haplotype (Cdx, GATA)   Number   BMD before treatment   BMD during treatment   P value
  ----------------------- -------- ---------------------- ---------------------- ---------
  AA                      10       − 1.2400 ± 1.68470     − 1.0000 ± 1.22927     0.496
  AG                      17       − 0.9882 ± 1.45167     − 0.8294 ± 1.19831     0.556
  GA                      15       − 1.1000 ± 1.40915     − 0.9067 ± 1.08593     0.454
  GG                      21       − 1.1524 ± 1.30561     − 1.1000 ± 1.08351     0.769
